FDA Offers To Expedite 'Priority' ANDA Reviews By Previewing Facility Information
Executive Summary
An FDA guidance lists the criteria for reviewing “pre-submission facility correspondence” that permits expedited approval of priority generic drugs by allowing facility information to be reviewed prior to the submission of an ANDA. This mechanism was established by GDUFA II.
You may also be interested in...
More ANDAs To Be Eligible For Priority Review, Gottlieb Says
US FDA Commissioner says agency has necessary resources to expand priority review pathway even as multiple review cycles for generic applications remain common.
More ANDAs To Be Eligible For Priority Review, Gottlieb Says
US FDA Commissioner says agency has necessary resources to expand priority review pathway even as multiple review cycles for generic applications remain common.
ANDA Sponsors Get Wide-Open Facility Deadline For Priority Review
User fee legislation says facility information to qualify for priority review must arrive two months in advance of ANDA, conflicting with narrow 'window' in FDA's draft guidance.